Semaglutide and hair loss: separating real risk from TikTok panic

What did @myrajoinmochi actually say?

The creator opened with a specific statistic: "almost 3% of patients who start on semaglutide" will lose their hair. From there, they offered four fixes: address vitamin and micronutrient deficiencies (specifically recommending a Costco Kirkland multivitamin), limit heat styling, use rosemary oil or minoxidil, and see a dermatologist if you notice clumps coming out, which they identified as possible telogen effluvium. They also explained that minoxidil "dilates the blood vessels at the base of your scalp" and warned that stopping Rogaine after starting it causes problems.

That's a fairly complete rundown for a TikTok. Some of it holds up. Some of it doesn't. And one piece, the 3% figure, is worth examining closely before you repeat it to your doctor.

Does the science back this up?

Partially, yes. Hair loss after rapid weight loss is real and well-documented, and the mechanism the creator points to, telogen effluvium, is the right one. But the 3% figure is shakier than it sounds.

The SUSTAIN and STEP clinical trials for semaglutide did report alopecia as an adverse event, but rates varied by trial and were not consistently reported as a standalone endpoint. A 2023 analysis by Wilding et al. in Diabetes, Obesity and Metabolism noted that hair loss events in STEP trials hovered between 3-5% in active treatment arms versus under 1% in placebo, suggesting the drug context matters, but those numbers were not uniform. The creator's "almost 3%" is within range but presented as more precise than the evidence supports. Rapid caloric restriction itself is a known trigger for telogen effluvium regardless of the drug involved, which the creator mentions but doesn't fully separate from semaglutide-specific effects.

On minoxidil: the mechanism description is roughly correct. Minoxidil is a vasodilator that prolongs the anagen (growth) phase of hair follicles. The warning about not stopping is real, supported by standard dermatology guidance.

What did they get wrong (or right)?

They got the telogen effluvium identification right. That's the actual dermatology consensus on GLP-1-associated hair loss, and the advice to see a dermatologist is genuinely good.

They got the minoxidil mechanism mostly right, though "dilates the blood vessels at the base of your scalp" is an oversimplification. The primary mechanism involves potassium channel opening and follicle cycle prolongation, not just vasodilation. It's a minor inaccuracy but worth noting.

The Kirkland multivitamin recommendation is where this gets problematic. Recommending a specific commercial product by brand name as the singular best option, with no supporting evidence, is not clinical guidance. It's a product plug dressed up as advice. Biotin supplementation has limited evidence for hair regrowth in people without a documented biotin deficiency (Patel et al., 2017, Skin Appendage Disorders). The creator doesn't mention that deficiency should be confirmed first.

The rosemary oil mention is actually defensible. A 2015 randomized trial by Panahi et al. in Skinmed found rosemary oil comparable to 2% minoxidil for androgenetic alopecia at six months, though this was not studied in the context of GLP-1-related hair loss specifically.

What should you actually know?

Hair loss on GLP-1 medications is most likely telogen effluvium from rapid weight loss, not a direct drug toxicity. That distinction matters because it changes the treatment approach and the timeline. Telogen effluvium typically resolves on its own within six to nine months once weight stabilizes, which the creator did not mention.

Before buying supplements, get labs. A full iron panel, ferritin, thyroid function, zinc, and B12 should be checked before assuming a multivitamin will fix anything. Ferritin below 30 ng/mL is independently associated with hair shedding (Rushton, 2002, Clinical and Experimental Dermatology), and that won't be corrected by a general multivitamin alone.

Minoxidil is an FDA-approved treatment and worth discussing with a dermatologist or your prescribing provider. The "you can never stop" framing is a real consideration but shouldn't be used to scare people away from a legitimate option. It means you need to make an informed, deliberate choice, not avoid the treatment entirely.

Heat tool advice is low-stakes and reasonable but will not address the underlying cause. Reducing mechanical damage is supportive care, not treatment.